Idrevloride is under clinical development by Parion Sciences and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Idrevloride’s likelihood of approval (LoA) and phase transition for Primary Ciliary Dyskinesia took place on 25 Nov 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Idrevloride Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Idrevloride overview

VX-371 (P-1037, GS-5737) is under development for the treatment of primary ciliary dyskinesia (PCD). The therapeutic candidate is administered through inhalational route as a solution. The drug candidate acts by targeting epithelial sodium channel (ENaC). It is developed based on ENaC inhibitor technology. It was under development for non-cystic fibrosis bronchiectasis (NCFB), cystic fibrosis and chronic obstructive pulmonary disease (COPD).

Parion Sciences overview

Parion Sciences is a development stage company that provides research, development and commercialization of treatments to improve patient’s innate mucosal surface defenses. The company’s pipeline products include P-1037, a clinical stage ENaC blocker for pulmonary disease and cystic fibrosis; tPAD, a trans-nasal pulmonary aerosol delivery system for inhaled drug delivery for cystic fibrosis; mucolytic agents for respiratory diseases; CFTR corrector program for cystic fibrosis; and P-321 for dry eye disease. Parion Sciences’ technologies target respiratory and ocular diseases in which the patient’s ability to protect their mucosal surfaces. The company has partnerships with research institutions, foundations and corporate, among others. Parion Sciences is headquartered in Durham, North Carolina, the US.

Quick View Idrevloride LOA Data

Report Segments
  • Innovator
Drug Name
  • Idrevloride
Administration Pathway
  • Inhalational
Therapeutic Areas
  • Respiratory
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.